◀ Back to IL6
IL6 — OSM
Protein-Protein interactions - manually collected from original source literature:
Studies that report less than 10 interactions are marked with *
Text-mined interactions from Literome
Fischer et al., Arthritis Rheum 1999
:
Furthermore,
OSM and IL-6
induced IL-6 synthesis in chondrocytes, resulting in an autocrine amplification loop
Bernard et al., Circ Res 1999
:
Oncostatin M induces
interleukin-6 and cyclooxygenase-2 expression in human vascular smooth muscle cells : synergy with interleukin-1beta ...
OSM stimulated the release of
IL-6 by hASMCs in a dose dependent way ; after a 48-hour exposure, values were 8.5+/-0.7, 29.7+/-3.5, 50.9+/-4.4, and 73.8+/-7.6x10 ( 3 ) U/mL ( n=6 ) at OSM concentrations of 0, 1, 10, and 100 ng/mL, respectively ... Interestingly,
OSM acted in synergy with IL-1beta on
IL-6 production and COX-2 expression
Ding et al., Cytokine 2000
:
Blocking protein tyrosine kinase ( PTK ) activation by herbimycin A or genistein, or blocking NF-kappaB activation by pyrrolidinedithiocarbamate, reduced the
IL-6 expression
induced by TNF-alpha, IL-1beta and
OSM
Van Wagoner et al., J Neurochem 2000
(Astrocytoma) :
Oncostatin M regulation of
interleukin-6 expression in astrocytes : biphasic regulation involving the mitogen activated protein kinases ERK1/2 and p38 ...
OSM induces
IL-6 protein expression in a dose- and time dependent manner in astrocytes ... In addition,
OSM can
synergize with the cytokines tumor necrosis factor-alpha, IL-1beta, and transforming growth factor-beta for enhanced
IL-6 expression ... These data demonstrate that
OSM induces
IL-6 expression in astrocytes and that the MAPKs ERK1/2 and p38 participate in this response
Klausen et al., Oncogene 2000
:
Inhibition of MEK activation completely abrogated OSM and
IL-6 induced p27kip1 accumulation, while expression of dominant negative STAT5 decreased the
OSM and IL-6 mediated inhibition of DNA-synthesis and partially inhibited p27kip1 accumulation
de Hooge et al., Am J Pathol 2002
(Arthritis...) :
OSM strongly
induced interleukin (IL)-6 gene expression, a known mediator of osteoclast development
Holub et al., Immunol Lett 2002
(Carcinoma, Hepatocellular...) :
In this study we found that
oncostatin M (OSM) , an other gp130 dependent cytokine with proliferation inhibitory potential,
increases the expression of both membrane bound
IL-6R and sIL-6R generated by alternative splicing in hepatic and mammary carcinoma cell lines
Schieven et al., J Immunol 1992
:
The tyrosine kinase inhibitor herbimycin A blocked the
induction of
IL-6 by
oncostatin M in HEC ... We conclude that
oncostatin M utilizes a tyrosine phosphorylation signal transduction pathway in HEC involving the activation of the p62yes tyrosine kinase, and that this tyrosine phosphorylation pathway
leads to the induction of
IL-6 expression
Faffe et al., Am J Physiol Lung Cell Mol Physiol 2005
:
Consistent with the increase in IL-1R1 expression,
OSM markedly
augmented IL-1beta induced VEGF, MCP-1, and
IL-6 release
Persson et al., Biochem Biophys Res Commun 2005
:
The
IL-6 protein release from calvarial osteoblasts was also
stimulated by the osteoclastogenic, proinflammatory cytokines IL-11, LIF,
OSM , IL-17, TGF-beta, and TNF-alpha
Smyth et al., J Immunol 2006
(Inflammation) :
In this study, we show that activation of the calcium independent or novel protein kinase C ( PKC ) isoform PKCdelta is a critical event during
OSM mediated up-regulation of
IL-6 expression in murine fibroblasts ... However, silencing of PKCdelta protein expression, but not the related novel isoform PKCepsilon, by use of RNA interference ( i.e., small interfering RNA ) demonstrated that PKCdelta is required for murine
OSM ( mOSM )
induction of
IL-6 protein secretion
Brown et al., J Immunol 1991
:
Regulation of
IL-6 expression by
oncostatin M
Migita et al., Arthritis Res Ther 2011
(Arthritis, Rheumatoid) :
CP690,550 pretreatment completely abrogated the
OSM induced production of
IL-6 , as well as OSM induced JAK/STAT, and activation of mitogen activated kinases ( MAPKs ) in FLS
Schulz et al., Journal of neuroinflammation 2011
:
OSM-treatment ( 100 ng/ml ; 24 h )
led to 30-fold increase of
IL-6 secretion from U343 cells
Richards et al., Cytokine 1994
:
The
role of
Oncostatin M (OM) , a monocyte/macrophage and T-cell product, in regulating
IL-6 expression in fibroblasts of lung or synovial origin was examined in vitro
Jay et al., Endocrinology 1996
(Bone Resorption) :
In these cultures,
OSM induced proliferation, collagen synthesis, and
interleukin-6 secretion, whereas it inhibited alkaline phosphatase activity
Levy et al., Endocrinology 1996
(Osteosarcoma) :
In osteoblastic cultures,
OSM causes marked phenotypic changes and the enhanced secretion of
interleukin-6
Gallo et al., J Invest Dermatol 1997
(Wounds and Injuries) :
interleukin-6 was identified as the phosphatase inducing factor in wound fluid and the related cytokines, leukaemia inhibiting factor, and
oncostatin M ,
caused a similar degree of alkaline phosphatase induction
Cichy et al., J Immunol 1997
(Carcinoma, Hepatocellular) :
It was found that
oncostatin M alone or in combination with the glucocorticoid analogue dexamethasone significantly
up-regulated IL-6R release